预约演示

更新于：2025-07-15

Clavulanate Potassium/Ticarcillin Disodium

替卡西林钠克拉维酸钾

更新于：2025-07-15

概要

基本信息

药物类型

小分子化药

别名

Ticarcillin Disodium and Clavulanate Potassium、Ticarcillin Disodium and Potassium Clavulanate、Ticarcillin Disodium/Clavulanate Potassium

+ [4]

靶点-

作用方式

抑制剂

作用机制

细胞壁抑制剂

治疗领域

感染呼吸系统疾病皮肤和肌肉骨骼疾病+ [2]

在研适应症-

非在研适应症

细菌感染骨和关节感染妇科感染+ [5]

原研机构

GSK Plc

在研机构-

非在研机构

GSK PlcSmithkline Beecham Pharmaceuticals (India) Ltd.

权益机构-

最高研发阶段撤市

首次获批日期

美国 (1985-04-01),

骨和关节感染妇科感染腹腔感染+ [4]

最高研发阶段(中国)撤市

特殊审评-

登录后查看时间轴

结构/序列

分子式C23H25N3O11S2

InChIKeyXWMVMWTVLSLJGY-FAJPTIRJSA-N

CAS号86482-18-0

关联

项与替卡西林钠克拉维酸钾相关的临床试验

TCTR20250410003

/ Active, not recruitingN/AIIT

Efficacy and Safety of direct drug provocation test in children with benign cutaneous immediate hypersensitivity reaction to Beta-lactams

开始日期2025-04-09

申办/合作机构-

NCT04879030

/ Completed临床2/3期IIT

Is Combination Antibiotic Therapy Superior to Monotherapy in the Treatment of Acute Exacerbations of Chronic Obstructive Pulmonary Disease

The investigators hypothesized that the empirical use of fluoroquinolones together with beta-lactam antibiotics will change their therapeutic success in patients with acute exacerbations of COPD compared to that in patients in whom a single beta-lactam treatment was used. The main goal of this study was to compare the clinical and bacterial success from the use of a combination of beta-lactam and fluoroquinolone antibiotics with that of a single beta-lactam treatment, in adult patients with COPD exacerbations.

开始日期2020-01-01

申办/合作机构-

NCT01963442

/ Unknown status临床2期IIT

A Non-Inferiority, Multicentered, Controlled, Randomized, Double Blinded Study Investigating the Antibiotic Treatment Duration (3-day Versus 8-day) for Subjects Admitted to Emergency Services With Acute Non-severe Community Acquired Pneumonia (CAP)

To investigate the non inferiority of a short lasting antibiotic treatment (3 days) when compared to a long lasting antibiotic treatment (8 days), at Day 15 after the beginning of treatment in terms of clinical efficacy, in adults admitted to emergency services for a non severe Community Acquired Pneumonia (PAC), who responded well to 3 days of beta-lactamin treatment (3GC or A/AC).

开始日期2013-11-01

申办/合作机构

Centre Hospitalier de Versailles

100 项与替卡西林钠克拉维酸钾相关的临床结果

登录后查看更多信息

100 项与替卡西林钠克拉维酸钾相关的转化医学

登录后查看更多信息

100 项与替卡西林钠克拉维酸钾相关的专利（医药）

登录后查看更多信息

6,948

项与替卡西林钠克拉维酸钾相关的文献（医药）

2025-12-01·MOLECULAR BIOLOGY REPORTS

Two case reports of biliary stent infections by extensively drug-resistant Escherichia coli carrying blaNDM-5 at a tertiary-care hospital in West Bengal, India

Article

作者: Das, Surojit ; Sarkar, Dipankar ; Mallick, Abhi ; Sarkar, Soma ; Saha, Puranjay

BACKGROUND:

Rising antimicrobial resistance (AMR) is an acute public health emergency impeding the clinical efficacy of surgical interventions. Biliary stent placement is one of the routine surgical procedures that rarely lead to infections that are empirically managed by broad-spectrum β-lactams and fluoroquinolones. Critical priority pathogens, such as carbapenem-resistant Escherichia coli challenge treatment outcomes and infection prevention.

METHODS AND RESULTS:

Two carbapenem-resistant Escherichia coli isolates recovered from biliary stent-infected patients were investigated for drug resistance and molecular typing from a tertiary-care hospital in eastern India. The isolates were extensively drug-resistant (XDR) and remained susceptible to aminoglycosides, tigecycline, fosfomycin, or colistin. Carbapenemase bla_NDM-5 was carried by both the isolates that either belonged to strain type ST361 or ST405.

CONCLUSIONS:

This is the first report of carbapenem-resistant Escherichia coli carrying bla_NDM-5 being recovered from biliary stent infections in India. Targeted antibiotic therapy is pivotal for the XDR infections, while molecular typing facilitates infection prevention measures by source tracking and control.

2025-09-01·European journal of obstetrics & gynecology and reproductive biology: X

Treatment strategies for intra-amniotic infection and/or inflammation in preterm labor cases

Article

作者: Niimi, Hideki ; Yoneda, Satoshi ; Yoneda, Noriko ; Saito, Shigeru

Spontaneous preterm birth (sPTB) is caused by multiple factors; however, the main cause is intra-amniotic infection and/or inflammation. The frequency of intra-amniotic infection/inflammation is higher in extremely sPTB (<28 weeks) and causes long-term cognitive impairments, such as cerebral palsy and mental retardation. The rate of intra-amniotic superinfections, such as Ureaplasma/Mycoplasma and bacteria, is high in sPTB < 27 weeks of gestation. Obstetrical strategies based on accurate information on intra-amniotic infection/inflammation are needed to prevent sPTB (particularly extremely sPTB) and improve the long-term prognosis of preterm infants. Our PCR method, which is sensitive and free from false positives, accurately identifies whether intra-amniotic infection is present. Appropriate antibiotic therapy against intra-amniotic infection (macrolides against Ureaplasma/Mycoplasma and beta-lactams against bacteria) in preterm labor (PTL) cases effectively prolongs the gestational period by 4 weeks. In contrast, the use of antibiotics shortens the gestational period in cases without intra-amniotic infection. We previously reported that 17-alpha-hydroxyprogesterone caproate (17OHP-C) effectively prolonged pregnancy by 4 weeks in PTL cases with mild intra-amniotic inflammation, but not in those with severe intra-amniotic inflammation. Treatment strategies based on accurate intra-amniotic information is expected to prolong pregnancy. However, obstetrical interventions are limited once severe clinical symptoms appear. In addition to the use of drugs to control uterine contractions, antibiotics and/or 17OHP-C may be necessary in the treatment of PTL cases following the accurate assessment of intrauterine infection and/or inflammation is confirmed.

2025-09-01·WATER RESEARCH

Temporal dynamics of class 1 and class 3 integron pools in treated wastewater

Article

作者: Henriques, Isabel ; Rodrigues, Elsa T ; Tavares, Rafael D S ; Tacão, Marta

Wastewater is a hotspot for the spread and evolution of antimicrobial resistance (AMR), with integrons playing a key role in the dissemination of AMR. However, there is limited information available regarding the integron pool of wastewater environments. The present study aims to characterize the integron pool in outflow secondary-treated municipal wastewater samples collected weekly over the course of a year (n = 52 samples) and to identify the risks associated with the carriage of clinically relevant antimicrobial resistance gene cassettes (ARGCs). Integron arrays were amplified with the primer combinations intI-R/3'CS and intI3F/class3R. PacBio long-read sequencing was performed on 12 monthly pooled samples per primer pair. The analysis yielded 283,579 integron reads, capturing an estimated 10%-20% of the total integron pool, with the most abundant arrays successfully recovered. Most identified GCs had no known function (33.3% to 74.5% depending on integron class). Regarding GCs with known function, AMR was the most prevalent function in class 1 integrons. Class 3 integrons primarily encoded defence mechanisms and amino acid transport and metabolism, while cassettes associated with replication, recombination and repair were abundant in integrons of unknown class. The prevalence of ARGCs for class 1, 3 and integrons of unknown class was 61.7%, 19.2% and 9.6%, respectively. Most ARGCs (from the 146 identified) encoded resistance to aminoglycosides and beta-lactams, the most abundant being aadA10, aac(6')-IIc and bla_GES-5. Most beta-lactamase-encoding GCs (BLGCs) identified encoded enzymes with carbapenemase and/or extended-spectrum activity, with class 1 and class 3 integrons being relevant reservoirs of BLGCs. GCs encoding proteins involved in oxidative stress repair, as well as in other functions, were also identified and might promote co-selection of ARGCs. Large variation of the integron arrays and the GC pool was observed between seasons and pooled monthly samples, with resistance genotypes such as macrolide and phenicol resistance differentially abundant across seasons. Overall, these findings show that secondary-treated wastewater is a reservoir of highly diverse class 1 and class 3 resistance integrons, some encoding critically relevant resistance mechanisms (e.g., carbapenemases).

项与替卡西林钠克拉维酸钾相关的新闻（医药）

2025-05-05

·ETPharma

Expert Panel bats to fast-track Clinical Trial approval with shorter permission timelines

New Delhi: In a bid to expedite approvals for clinical trials involving new and investigational drugs, the country’s apex drug advisory body has proposed streamlining the application process and cutting the approval timeline by up to 50 per cent. At its 92nd meeting, the Drugs Technical Advisory Board ( DTAB ) recommended reducing the timeline for granting permission to manufacture new drugs and investigational new drugs for clinical trials and BA/BE studies from 90 working days to 45. The board also proposed introducing a "notification system" for applications to manufacture drugs for analytical and preclinical testing—excluding sex hormones, cytotoxic drugs, beta-lactams, biologics with live microorganisms, and narcotic and psychotropic substances. Under Chapter VIII of the New Drugs and Clinical Trials Rules, 2019, entities must obtain approval from the Central Licensing Authority ( CDSCO ) to manufacture or import new or investigational drugs for clinical trials. The approval is subject to conditions including compliance with Good Manufacturing Practices (GMP) and other relevant standards. Chapter VIII details the requirements for manufacturing and importing new or investigational drugs for clinical trials or bioavailability/bioequivalence studies, mandating central licensing authority approval. Meanwhile, the DTAB reiterated that all antimicrobials must be classified as “New Drugs” under the New Drugs and Clinical Trials Rules, 2019, in the public interest, and recommended corresponding changes to the rules. This recommendation followed growing concern over antimicrobial resistance due to the misuse of antibiotics, antivirals, antifungals, and more—an issue highlighted in the G20 declaration. At its 91st meeting in September 2024, the DTAB referred the matter to the Drugs Consultative Committee (DCC), CDSCO’s internal advisory body on drug regulation. In its latest meeting, the DCC recommended that provisions be included in the rules to enable CDSCO’s regulatory oversight over antimicrobial approvals, ensuring consistent implementation and compliance across the country. By Online Bureau ,

加速审批

2025-03-24

·PRNewswire

B. Braun Launches Ready-to-Activate Cefazolin 3 Gram Pre-Mix in DUPLEX® Containers

BETHLEHEM, Pa., March 24, 2025 /PRNewswire/ -- B. Braun Medical Inc. (B. Braun), a leader in smart infusion therapy and pain management, announced the launch of its new Cefazolin 3 g, the latest cefazolin dose addition to the DUPLEX® Container portfolio. Cefazolin is prescribed to prevent infections before, during or after surgery. B. Braun offers Cefazolin in 1 g, 2 g and now 3 g strength which is indicated for patients with body weight equal to or greater than 120 kg. The delivery of Cefazolin 3 g in the DUPLEX Container helps to ensure fast, simple and accurate administration with the added convenience of the right dose at the right time. The DUPLEX Container is a ready-to-activate, two-compartment, flexible IV system that keeps pre-measured medication and diluent separate until ready to administer. Designed for easy stocking, DUPLEX Containers can be stored at room temperature with a minimum shelf life of 18 months and are compatible with automated medication dispensing systems. "We are excited to add Cefazolin 3 g to our DUPLEX Container portfolio which allows us to address a previously unmet need for patients weighing 120 kg or more. DUPLEX Containers offer healthcare workers an easy-to-use solution that is activated at the bedside with no need for complicated reconstitution or messy thawing - saving time and labor for practitioners while reducing potential dosing errors," said Shawn Brinson, Director of Marketing, Injectable Drugs. Cefazolin 3 g in DUPLEX Containers keeps premeasured medication and diluent separate until the healthcare worker is ready to administer at the bedside by simply folding, squeezing and shaking to reconstitute. A barcode referencing the final admixture, lot number and expiration date helps reduce medication errors, automate patient charting, track inventory and facilitate reimbursement tracking. For additional information, please see full Prescribing Information. IMPORTANT SAFETY INFORMATION Contraindications: Know hypersensitivity to cefazolin or other cephalosporin class antibacterial drugs, penicillin or other beta-lactams. About B. Braun B. Braun Medical Inc. (B. Braun) is a leader in smart infusion therapy and safe and effective pharmacy products, patient and provider safety, and sustainable health solutions. Our purpose is to help providers constantly improve patient satisfaction and outcomes. With products and services created to help healthcare professionals focus on what matters most—their patients—we're uniquely positioned to help health systems succeed now and in the future. B. Braun is headquartered in Bethlehem, Pennsylvania and is part of the B. Braun Group of Companies in the U.S., which includes B. Braun Interventional Systems, Aesculap ® and CAPS ®. The company employs 8,500 people at over 30 locations across North America. Globally, the B. Braun Group of Companies employs more than 64,000 employees in 64 countries. Guided by its Sharing Expertise ® philosophy, B. Braun continuously exchanges knowledge with customers, partners and clinicians to address the critical issues of improving care and lowering costs. To learn more about B. Braun Medical, explore our website. SOURCE B. Braun Medical Inc. WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

上市批准

2025-01-23

·健识局

红三星预警！中药挂网价超出同行10倍，被暂停采购

1月21日，江苏省药品医用耗材阳光采购服务网发布《2025年第一批药品预警情况》，共有73个品规的药品被纳入预警名单。健识局注意到：本次预警名单以中药品种为主，其中有4个品种被红三星预警，8个品种被标记为红二星，24个品种被标记为红一星，37个被标记为黄色预警。根据江苏省医保局2021年印发《关于深入推进药品阳光采购的实施意见》明确，对挂网药品价格动态监测，实行价格预警管理，涉及了“几颗星”的预警规则：高于同品种挂网价格10倍以上，标记为红色三星；高于已挂网价5倍至10倍的标记为红色二星；2倍至5倍的标记为红色一星。按照规则，标注红三星的将暂停交易，医疗机构原则上不得采购；二星和一星的企业要被约谈，医疗机构谨慎采购。这次被警告的，不乏广州白云山、天津同仁堂等众多知名药企的大品种。 2024年，江苏省医保局已发布46批药品价格预警名单，接近2000个产品被点名。上海、山东、四川、安徽、贵州等省市均采取类似的预警规则。 73个药品触发价格预警江苏这次对4个品种标注为价格预警红三星，分别是：兰州太宝制药有限公司两个规格的川芎茶调丸、广盛原中医药有限公司的健脾丸、河北唐威药业有限公司的健脾丸。这几个品种将被暂停挂网。健脾丸是一种常用中药，国内至少有上百个批号，同仁堂、天士力、东阿阿胶等大型中药企业都有生产。川芎茶调丸生产企业少一些，但也有佛慈、太极等大厂生产。4个品种暂停挂网不会对药品临床使用造成太大影响。而且这4个品种不会彻底“出局”。分析人士指出，价格预警机制实行动态管理，企业主动调整挂网价格后，平台将根据实际情况，按规定重新确定预警状态。 8个品种被标记为红二星的分别是：健脾丸、金果饮、清宁丸、乳宁胶囊、注射用替卡西林钠克拉维酸钾。24个品种标记为红一星，主要是骨刺片、生脉饮(党参方)、天麻胶囊、生脉饮、蛇胆川贝枇杷膏等中药。还有37个被点名药品因价格高于已挂网最高价但不足2倍触发黄色预警，涉及小儿消食颗粒、血塞通滴丸、鸦胆子油软胶囊、一清片等知名品种。药品挂网价格大幅偏高的原因很多，有业内人士向健识局坦诚：一些企业由于人手不足，导致在各地的药品价格维护不及时；也有部分药企抱有侥幸心理，寄希望逃避监管，估计不降价或晚降价。事实上，各省市药品挂网平台已初步做到价格实时联网，稍有差异就能及时反馈。因此，业内普遍认为，2024年在全国范围内开展四同药品挂网整治行动之后，所有企业应规范自身产品的挂网报价机制，否则将会面临暂停销售的危机。监管风暴刮向中成药中成药价格高，已经是不少患者在看病过程中最深切的感受。比起化学药来，中成药很多是独家供应、区域供应，长期以来中成药的价格难以调控，经常是按起葫芦又起瓢。目前各省市挂网平台的价格数据互联互通，任何品种的价格监管已达到无死角的高压态势。这至少可以解决一部分省与省之间价格差距过大的问题。江苏、上海、山东、山西、四川、贵州、安徽等省都采取了类似颜色预警机制。按照国家医保局的整改目标，最小制剂单位价格，应当调整到不高于已整改价格的药品价格的1.8倍以内。健识局获悉，今后跨区域的药品价格长效监测机制将逐步建立，同时，在医保部门推动下，针对不同包装的药价精细化管理预计也将覆盖更多药品类别。江苏在近日召开的全省医疗保障工作会议上明确，2025年要深化医药价格改革治理，推进药品价格预警全覆盖。1月1日，江苏发布《关于做好定点药店医保药品量价比较指数工作的通知》，要求自今年起将在不高于全省量价比较指数监测预警线的基础上，确定量价比较指数监测值，开展定点药店医保药品价格监测。对于挂上红星和黄星的药企，医保部门会通过核查、约谈等方式引导调整不合理的药品价格，将量价比较指数保持在合理范围，对拒绝调整价格或调整后仍未符合要求的，将根据协议约定给予相应处理，规范定点药店价格行为。日前，全国医疗保障工作会议明确了2025年八大医保重点工作，其中“深化医药价格改革治理，不断规范医药价格秩序”被列入。可以预见，随着医保部门不断推进价格治理专项行动，挤掉药品虚高水分，百姓购药负担将进一步减轻。撰稿丨小米编辑丨江芸贾亭运营｜王苗嫦插图｜视觉中国声明：健识局原创内容，未经许可请勿转载单品大卖超30亿元，艾力斯却还没碰到及格线？以岭药业十年高盈利的业绩神话，结束了新事 | 信达生物新药启动与K药“头对头”试验

带量采购生物类似药

100 项与替卡西林钠克拉维酸钾相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	替卡西林钠克拉维酸钾	J01CR03	-

研发状态

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
细菌感染	中国	Smithkline Beecham Pharmaceuticals (India) Ltd.	2000-05-16
骨和关节感染	美国	GSK Plc	1985-04-01
妇科感染	美国	GSK Plc	1985-04-01
腹腔感染	美国	GSK Plc	1985-04-01
下呼吸道感染	美国	GSK Plc	1985-04-01
脓毒症	美国	GSK Plc	1985-04-01
皮肤和皮肤结构感染	美国	GSK Plc	1985-04-01
泌尿道感染	美国	GSK Plc	1985-04-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT02158442 (CTgov)	临床2期	糖尿病 \| 软组织感染 \| 伤口感染 ... 更多	15	Percutaneous Isolated Limb Perfusion (PILP) delivery+Timentin (Treatment Group)	壓構構壓窪遞鏇網願壓 = 鑰齋鏇製淵範壓蓋築願淵構壓齋觸醖窪製願膚 (積鹹築醖網醖鑰廠鬱憲, 築鏇製簾製觸壓構艱選 ~ 顧範衊獵鹽網繭膚艱膚) 更多	-	2016-08-03
				Timentin (Control Group)	壓構構壓窪遞鏇網願壓 = 餘壓醖餘鑰願顧鬱蓋範淵構壓齋觸醖窪製願膚 (積鹹築醖網醖鑰廠鬱憲, 襯艱顧鬱艱簾獵淵鹹鑰 ~ 製選餘鬱願選艱鑰醖願) 更多